Using chimeric antigen receptor T-cell therapy to fight glioblastoma multiforme: past, present and future developments.

ABSTRACT:

Introduction

Glioblastoma multiforme (GBM) constitutes one of the deadliest tumors to afflict humans, although it is still considered an orphan disease. Despite testing multiple new and innovative therapies in ongoing clinical trials, the median survival for this type of malignancy is less than two years after initial diagnosis, regardless of therapy. One class of promising new therapies are chimeric antigen receptor T cells or CAR-T which have been shown to be very effective at treating refractory liquid tumors such as B-cell malignancies. However, CAR-T effectivity against solid tumors such as GBM has been limited thus far.

Methods

A Pubmed, Google Scholar, Directory of Open Access Journals, and Web of Science literature search using the terms chimeric antigen receptor or

SUBMITTER: Soler DC 

PROVIDER: S-EPMC8714623 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature